Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66807-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- PABPN1 antibody
- Antibody type
- Monoclonal
- Description
- KD/KO validated PABPN1 antibody (Cat. #66807-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, Mouse, Rat and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 3C12E12
- Vial size
- 20ul, 150ul
Submitted references Nuclear effects play an important role in determining codon usage-dependent human gene expression.
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex.
PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.
An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus.
Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.
Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
Garg R, Xie P, Duan J, Liu H, Liu Y
Nature communications 2025 Dec 3;16(1):10865
Nature communications 2025 Dec 3;16(1):10865
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex.
Papadopoulos D, Ha SA, Fleischhauer D, Uhl L, Russell TJ, Mikicic I, Schneider K, Brem A, Valanju OR, Cossa G, Gallant P, Schuelein-Voelk C, Maric HM, Beli P, Büchel G, Vos SM, Eilers M
Molecular cell 2024 Jun 6;84(11):2070-2086.e20
Molecular cell 2024 Jun 6;84(11):2070-2086.e20
PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.
Chen L, Dong W, Zhou M, Yang C, Xiong M, Kazobinka G, Chen Z, Xing Y, Hou T
Cell & bioscience 2023 Mar 6;13(1):45
Cell & bioscience 2023 Mar 6;13(1):45
An mRNA processing pathway suppresses metastasis by governing translational control from the nucleus.
Navickas A, Asgharian H, Winkler J, Fish L, Garcia K, Markett D, Dodel M, Culbertson B, Miglani S, Joshi T, Yin K, Nguyen P, Zhang S, Stevers N, Hwang HW, Mardakheh F, Goga A, Goodarzi H
Nature cell biology 2023 Jun;25(6):892-903
Nature cell biology 2023 Jun;25(6):892-903
Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
Tang B, Lee HO, Gupta S, Wang L, Kurimchak AM, Duncan JS, Kruger WD
The Journal of biological chemistry 2022 Sep;298(9):102367
The Journal of biological chemistry 2022 Sep;298(9):102367
Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.
Ho JJD, Cunningham TA, Manara P, Coughlin CA, Arumov A, Roberts ER, Osteen A, Kumar P, Bilbao D, Krieger JR, Lee S, Schatz JH
Cell reports 2021 Oct 12;37(2):109806
Cell reports 2021 Oct 12;37(2):109806
Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
Wheeler JM, McMillan P, Strovas TJ, Liachko NF, Amlie-Wolf A, Kow RL, Klein RL, Szot P, Robinson L, Guthrie C, Saxton A, Kanaan NM, Raskind M, Peskind E, Trojanowski JQ, Lee VMY, Wang LS, Keene CD, Bird T, Schellenberg GD, Kraemer B
Science translational medicine 2019 Dec 18;11(523)
Science translational medicine 2019 Dec 18;11(523)
No comments: Submit comment
No validations: Submit validation data